Cycle on May 26, 2026

Let me start by searching for the latest GLP-1 news since the last cycle (May 25). I'll run several searches in parallel across key dimensions

Good — I can see several fresh leads. Let me pull the most promising ones for full reading

Let me continue pulling the most substantive new leads. I'll fetch the cancer study details and the Science Daily AI Reddit side effects story, plus check on new competitive developments.

Let me continue pulling key sources — the GLP-1 obesity scorecard, the EU Wegovy pill recommendation, and the Hims & Hers deal with Novo Nordisk.

Let me pull a few more specific pages to substantiate the key findings.

Let me pull a few more key sources to round out the findings

Now I have a clear picture of this cycle's new material. Let me write the key findings. Several are genuinely novel — the cancer signal is the biggest story, plus major EU regulatory wins for Novo, a mechanism discovery at NIH, and the closing window on compounding.

Now let me handle threads — I should record a new thread about the cancer signal, and update the existing threads

Good — the two existing threads are still pending catalysts (Medicare Bridge hasn't launched yet, and TRIUMPH-2/3 + CagriSema decision haven't occurred). I'll leave those open and finish the cycle

Cycle complete. Here's what surfaced this round: **8 findings written across 7 dimensions:** | # | Finding | Investor Signal | |---|---------|----------------| | 1 | **GLP-1s linked to lower cancer progression** — Cleveland Clinic study: 50% lower lung cancer progression, 43% lower breast cancer vs. DPP-4 controls | 🚨 New TAM frontier — oncology is not priced into consensus | | 2 | **NIH uncovers cAMP mechanism** for GLP-1 weight loss in area postrema neurons; PDE4 inhibitor roflumilast extends the effect | Opens pathway to combination therapies that break plateaus | | 3 | **Novo dual EU CHMP wins**: Wegovy pill (16.6% WL, first oral in EU) + Wegovy 7.2 mg pen (20.7% WL, 31% ≥25%) | EU launches H2 2026 — material commercial expansion for battered NVO stock | | 4 | **FDA compounding crackdown accelerating**: 30 warning letters to telehealth firms, proposed 503B exclusion of all three major molecules | Pricing-power-positive for Lilly & Novo branded products | | 5 | **Viking Therapeutics M&A thesis**: oral VK2735 12.2% WL at 13 weeks (no plateau), Phase 3 enrolled, $603M cash, Polymarket takeover favorite | Speculative M&A play — oral dual agonist is the differentiator | | 6 | **AI finds hidden GLP-1 side effects** on Reddit (Nature Health): menstrual changes, chills, fatigue — hypothalamus-mediated, causation unproven | Early-warning signal; could affect adherence in women if confirmed | | 7 | **GLP-1 anti-inflammatory effects** in osteoarthritis (Cell Metabolism): cartilage protection independent of weight loss | Opens rheumatology indication pathway | | 8 | **Novo + OpenAI partnership** / **Hims launches generic semaglutide in Canada** (C$149/mo, first in G7) | AI is operational not financial catalyst; Canada generic signals patent erosion timeline | **2 new threads opened** for future cycles: GLP-1 oncology evidence track, and regulatory response to AI-identified side effects. The two existing threads (Medicare Bridge July 1 launch, TRIUMPH-2/3 and CagriSema FDA decision) remain open — none of those catalysts have triggered yet.